The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Priorities for the National Vaccine Plan
The Charge to the Committee
The federal government issued “Disease Prevention through Vaccine Development and Immunization, The US National Vaccine Plan” in 1994. The Institute of Medicine will convene an ad hoc committee to evaluate the 1994 National Vaccine Plan and then review and make recommendations regarding an update of this National Vaccine Plan. The committee will hold workshopsa with national expert stakeholders in medicine, public health, and vaccinology to review a publicly available, draft update of the Plan. The committee will prepare a letter report of the evaluation of the 1994 Plan, and a report with conclusions and recommendations about priority actions within the major components of the draft Plan.
a The IOM Committee on Review of Priorities in the National Vaccine Plan conducted its work between March 2008 and November 2009, including five information-gathering meetings with national stakeholders in Washington, DC, Chicago, Seattle, and Irvine.
and another that reflects NVPO’s role as a crucial ingredient in implementing the plan and ultimately ensuring that its objectives are achieved.
Vaccination is a fundamental component of preventive medicine and of public health practice. The use of vaccines to prevent infectious diseases has resulted in dramatic decreases in disease, disability, and death in the United States and around the world. The contemporary national vaccine program3 is extraordinarily complex in all aspects, from research and development of new vaccines to financing and reimbursement of immunization services. As a medical product, preventive vaccines occupy a unique niche because they are given to healthy individuals, they are purchased in large volume by the federal government as part of the Vaccines for Children entitlement program, and government public health agencies at the federal and state level make policy decisions about how best to use vaccines to protect the public’s health. Similar considerations inform policy for global vaccine efforts.
In the latter part of 2009, the political, economic, and social environment presents both opportunities for and challenges to strengthening the U.S. system for developing, manufacturing, regulating, distributing, funding,
In this report, the committee uses national vaccine program in lower case to denote the vast and complex network of actors and actions related to vaccines and immunization, and uses National Vaccine Program (per the 1986 act) when referring to the governmental agencies that have responsibilities related to vaccines and immunization.